Ascletis Pharma Inc.

Investors

Financials & Filing

2025

2024

2023

2022

2021

2020

2019

2018

Poll Results of Annual General Meeting Held on May 22, 2025
2025-05-22
Voluntary Announcement - Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
2025-05-20
Voluntary Announcement - Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
2025-05-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025
2025-05-06
Next Day Disclosure Return - Others
2025-04-30
Next Day Disclosure Return - Others
2025-04-29
Next Day Disclosure Return - Others
2025-04-28
Annual Report 2024
2025-04-28
Form of Proxy for the 2025 Annual General Meeting
2025-04-28
Notice of 2025 Annual General Meeting
2025-04-28

2

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1